{"id":"W4405038688","doi":"10.1182/blood-2024-206911","title":"Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Chugai Pharmaceutical; Teijin Pharma; Eisai; Sierra Oncology; Novartis Pharma; Otsuka Pharmaceutical; JCR Pharmaceuticals","keywords":"Polycythemia vera; Medicine; Transferrin receptor; Antibody; Internal medicine; Transferrin; Soluble transferrin receptor; Immunology; Anemia; Iron deficiency; Iron status","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007132222,0.0006970772,0.00103376,0.0002332174,0.0002971692,0.0005975954,0.000437767,0.0008495747,0.002229796],"category_scores_gemma":[0.0006250216,0.000259994,0.0006431727,0.0002507126,0.0004827186,0.0004066628,0.0001730397,0.001946919,0.0004385737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006615729,"about_ca_system_score_gemma":0.001140713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005555554,"about_ca_topic_score_gemma":0.001100024,"domain_scores_codex":[0.9997807,0.0001038507,0.00001070986,0.00004106442,0.00002629293,0.00003730801],"domain_scores_gemma":[0.9995642,0.00009412808,0.00009057494,0.00003388327,0.00003668854,0.0001804572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5340816,0.09190121,0.01750007,0.001401124,0.001737716,0.001450131,0.0006920588,0.004101545,0.1651162,0.0006714285,0.007408846,0.173938],"study_design_scores_gemma":[0.2380724,0.724313,0.0194966,0.00004376219,0.0004543694,0.001157403,0.00007669239,0.001843773,0.009493902,0.0002401471,0.004781787,0.00002634052],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938943,0.001530983,0.000894497,0.0002433294,0.0000593436,0.001302823,0.0005784115,0.00007947809,0.001416799],"genre_scores_gemma":[0.9955362,0.0006655036,0.00076244,0.0004354936,0.0000708274,0.0007706873,0.0006875307,0.00001258592,0.001058729],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002229796,"threshold_uncertainty_score":0.007459462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007775493434966133,"score_gpt":0.2774428740026725,"score_spread":0.2696673805677063,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}